Ingenix Raises €13M for AI Biology Reasoning Engine

Ingenix, an artificial intelligence firm focused on deciphering biological complexity, has successfully closed a €13 million seed-extension funding round. The investment was spearheaded by prominent life sciences venture capital firm Sofinnova Partners, with significant contributions from Inovo VC and OTB VC. This capital infusion is earmarked to accelerate the development of Ingenix's proprietary Biological Reasoning Engine and expand its collaborative efforts with pharmaceutical and biotechnology partners through a newly launched Qualified Access Program.

The company's core innovation, the Biological Reasoning Engine, is built upon a novel AI architecture termed 'Modality Fusion.' This approach diverges from conventional large-scale model training, which often assumes biological systems will conform to data volume. Instead, Modality Fusion integrates specialized AI models across diverse biological data types and scales, enabling direct reasoning across their distinct representations. This architecture is designed to tackle the inherent complexity and non-linguistic nature of biology, a challenge that single, monolithic AI models struggle to address.

In a compelling demonstration of its capabilities, Ingenix recently applied its engine to a complex oncology challenge involving dual-payload antibody-drug conjugate (ADC) prioritization for a biotech partner. The partner faced a daunting task of evaluating thousands of potential payload configurations, a process that had consumed years and substantial financial resources. Ingenix's engine, operating on first principles of biology rather than mere pattern matching, rapidly identified 15 candidate combinations. A subsequent blind review by the biotech's translational science team revealed that 5 were novel hypotheses, 3 of which were deemed actionable, showcasing the engine's ability to generate significant value in a fraction of the time previously required.

This efficiency gain is particularly noteworthy. The insights generated by Ingenix's engine in minutes would have typically taken the biotech firm several years and millions of euros to uncover through traditional research methods. This rapid acceleration is a testament to the power of the Modality Fusion architecture in navigating intricate biological questions, especially in nascent fields like dual-payload ADCs where extensive training data is scarce.

The funding will also support the expansion of Ingenix's Qualified Access Program. This initiative aims to provide select partners with access to the Biological Reasoning Engine, enabling them to address critical research and development questions. Piotr Surma, CEO and co-founder of Ingenix, emphasized the company's foundational belief that biology necessitates an AI architecture specifically designed for its unique characteristics, rather than adapting general-purpose models. He highlighted that early results have surpassed expectations, fueling excitement for broader application.

Simon Turner, Partner at Sofinnova Partners, commented on the strategic importance of Ingenix's work, stating, "It is no longer enough to just build models. Ingenix is building the reasoning layer, the part that actually connects the biology, the chemistry, and the clinical data into something a scientist can interrogate and act on. That's the hard bit, and that's where the value compounds." This perspective underscores the market's growing demand for AI solutions that provide actionable insights and facilitate scientific discovery, moving beyond mere data processing.

Ingenix's founding team brings a wealth of expertise, including key members from Applica, an AI company acquired by Snowflake in 2022, whose TILT model was instrumental in achieving the GPT-4 benchmark. This deep technical background positions Ingenix to lead in the specialized field of AI for biological understanding, a sector poised for significant growth as drug discovery and development increasingly rely on advanced computational tools.